EDGE Unveils First UAE-made Family of Smart Loitering Munitions at IDEX 2021
21.2.2021 19:08:00 EET | Business Wire | Press release
EDGE, an advanced technology group for defence and beyond, today launches its first family of multirotor loitering munitions, the QX range. In addition, Shadow 50 and Shadow 25, Rash 2 gliding munition kit, as well as new variants of the RW24 range – all designed and manufactured in the company’s first year of operations – were unveiled on the first day of the International Defence Exhibition and Conference (IDEX 2021), that is underway at the Abu Dhabi National Exhibition Centre until 25 February.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210221005030/en/
EDGE launches QX range- its first family of multirotor loitering munitions (Photo: AETOSWire)
The unveiling of the Class-1 electric unmanned aerial vehicles (UAVs) took place at the EDGE pavilion in the presence of His Excellency Faisal Al Bannai, CEO and Managing Director of EDGE and Ali Al Yafei, CEO of ADASI.
His Excellency Faisal Al Bannai, CEO & Managing Director, EDGE, said: “Right now, drone technology is revolutionising our world with the full potential of unmanned and autonomous capabilities still to be further explored – not just in the military sector, but the commercial sector too.”
He added: “Through launching the first UAE-made family of smart loitering drones, EDGE marks a significant milestone as a key technology enabler and in boosting the country’s autonomous capabilities and AI integration. With the future increasingly relying on unmanned systems that provide a higher degree of tactical flexibility, we have invested extensively to fast-track R&D investments in these domains, bringing related products to market with speed.”
The QX family of loitering munitions comprises four products: QX-1, a micro-UAV, QX-2, a mini-UAV, QX-3, a small UAV, and QX-4, which features an impressive vertical take-off and landing (VTOL) fixed wing. The precision-guided systems use sophisticated AI algorithms to target and strike, boasting an accuracy of 1 m CEP (circular error probable) – with an aim similar to laser guided munitions. Built to launch in any environment or terrain, the entire QX family of UAVs are lightweight, man portable, and comprise VTOL capabilities.
The second range of loitering munitions consists of Shadow 50 and Shadow 25. As the name implies, Shadow 50 can carry a payload of 50kg – exactly double its counterpart. Shadow 25 is a high-speed system equipped with a jet engine and boasts a short reaction time. Delivering high precision strike against fixed targets and advanced guidance capabilities, these UAVs leverage Global Navigation Satellite Systems (GNSS) and can fly using video navigation systems in GPS denied Environment.
Also launched on Day 1 of IDEX, the Rash 2 is a fixed-wing guidance kit for mortars and other in-house designed payloads, capable of gliding in flight and directing munitions to ground targets, available in different sizes to accommodate varying payload capacity, range, and endurance. ADASI has secured AED 55 million contract to supply Rash 2 to the UAE Armed Forces, marking the first order of the newly launched product.
Three new additions to the RW-24 range were also launched in time for IDEX 2021. The newly unveiled RW-24 Seeker is equipped with a thermal automatic seeker that enable greater accuracy of engagement of moving targets and increased functionality within GPS-denied environments.
The RW-24 Extended Warhead and RW-24 Extended Range variants increase the payload capacity from 8 kg to 13 kg, enabling the drone to carry additional fuel or to increase the size of the warhead.
EDGE is an advanced technology group that ranks among the top 25 military suppliers in the world.
About EDGE
EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005030/en/
Contact information
Thushara Mohanan
media@edgegroup.ae
+971-555080413/ +971-55-3584520
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom